Skip to main content

Advertisement

Table 1 Clinical characteristics of the patients in the CERTIM multi-cancer cohort

From: The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

  N (%)
Sex
 M 38 (66%)
 F 20 (44%)
Age (year)
 Median (range) 66 (41–83)
Tumor type
 Non-small cell lung 37 (64%)
 Small cell lung 1 (2%)
 Melanoma 5 (9%)
 Colon 1 (2%)
 Renal 10 (17%)
 Urothelial 4 (7%)
ECOG performance statusa
 0 2 (3%)
 1 31 (54%)
 ≥ 2 24 (42%)
Previous lines of therapy
 0 2 (3%)
 1 31 (53%)
 2 11 (19%)
 ≥ 3 14 (24%)
Anti-PD-1
 Nivolumab 52 (90%)
 Pembrolizumab 6 (10%)
ORR
 CR 6 (10%)
 PR 7 (12%)
 SD 7 (10%)
 PD 38 (65%)
  1. aECOG status was not available for 1 patient